Developing and maintaining cell lines for therapeutic bioproduction and biomedical research requires efficiency and accuracy. By automating the processes and techniques used in biomolecular research, scientists can achieve standardization, which can improve the speed, quality, and cost of drug discovery.
Hypoactive sexual desire disorder affects 10% of women in the United States and significantly...
Gibson Assembly is a rapid and reliable method for the assembly of DNA fragments in a single-...
While physicians stay informed about the medications they prescribe to ensure that patients...
Advances in biotechnology, together with an improved understanding of the underlying biology of disease, have led to the pursuit of more effective targeted therapeutics and the subsequent development of companion diagnostics to identify appropriate patients.
Recent meetings have provided a showcase for many potential druggable tumor targets. The range of potential new drug targets has been expansive, especially if one counts the whole-exome sequencing work being performed for the Cancer Genome Atlas project.
Drug developers have been in a quandary for some years now. The Human Genome Project offered novel insights into disease, including numerous tantalizing targets for therapeutic intervention. Unfortunately, many of these are protein-protein interactions not readily addressed by conventional “Rule of 5” small-molecule drugs.
Companion diagnostic tools allow companies to increase their chances of drug approval by targeting the right patients early. Developing the strategy, timing, and resources necessary for companion diagnostics success begins with understanding the mechanisms that successful companies use to build their programs.
Despite advances that have been made in sunscreen technology and growing public awareness of the need for sunscreen, recent data have found that the average U.S. lifetime risk of invasive melanoma has increased from 1 in 600 in 1960 to 1 in 50 in 2008.
The appeal of cell culture–based production of drugs has increased demand for single-use bioreactors that can move into the process-development lab and help manage peaks and tight development schedules. Single-use bioreactors can be used for monoclonal antibodies, recombinant proteins, stem cells, and vaccines.
The U.S. Food and Drug Administration cannot determine whether its four-year-old Risk Evaluation and Mitigation Strategies program is working because drug companies have not provided key information when requested and the agency has not taken enforcement action against them.
Apoptosis, or programmed cell death, plays an essential role in organismal development and tissue homeostasis. During development, apoptosis is critical for the sculpting of organs and the elimination of unnecessary structures. Many cells die an altruistic death daily to secure homeostasis of the whole organism.
A key function of heat shock proteins (HSPs) is to act as molecular chaperones to assist in the folding and stabilization of numerous client proteins. One family of HSPs—heat shock protein 90—stabilizes a diverse range of client proteins, many of which are involved in key pathways in malignancy.
The neverending din of partisan squabbling coming out of Washington can be deafening at times. Luckily for everyone, legislation like The Food and Drug Administration Safety and Innovation Act of 2012 seemed more or less immune to this cacophony, passing the Senate with 92 yay votes.
The day-to-day pressures on a compound manager come from several directions. There is pressure to support the increasing demands for samples in more diverse delivery formats; pressure to keep operational and supply costs down; and there has been the unfortunate trend toward staff reductions.
Scientists recently demonstrated that biphasic vesicles can deliver large-molecule or macromolecule drugs into the skin. Success with biphasic vesicles offers the potential for needle-free administration of many pharmaceuticals that could previously only be administered by injection.
Predicting the side effects of drugs remains one of the industry’s greatest challenges, with a large percentage of new drugs failing in clinical studies due to cardiac toxicity. The overall success rate from Phase 1 studies is only 11%, with 30% of these failing for safety reasons.
Drug discovery and development depends increasingly on imaging, from traditional microscopy to high-content screening. Moreover, these techniques provide sophisticated capabilities. To make the most use of these tools, researchers need advanced software that provides automation, analysis, and ease-of-use.
While the latest antiviral treatments can drop HIV levels to near undetectable levels, these drugs are a life sentence. Stop taking them and the virus comes raging back. New techniques are offering patients something previously thought impossible: a drug-free cure.